Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exelixis, Inc.

https://www.exelixis.com/

Latest From Exelixis, Inc.

BMS Sighs In Relief As Opdivo Returns To Sales Growth

With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.

Sales & Earnings Business Strategies

Mead Johnson's Quick Response To Nestlé Nutrition Formula Claim Challenge Isn't Swift Enough

Mead Johnson pulls challenged claims before National Advertising Division began a review in its SWIFT process, but not before Nestlé Nutrition, which markets Gerber infant formula, submitted its challenge.

Ad Complaints Commercial

Supplement OWL Progress: Mirror For Industry Support For Transparency, Mandatory Registration?

Advisory board for CRN-operated Supplement OWL recently reached out to industry for “ultimate reason” of recruiting participation. “Transparency has never been more important and this registry is a demonstration of this industry’s commitment to candor and honesty with our regulators, retailers and consumers,” they say.

Dietary Supplements Regulation

Earlier Use of Exelixis/Ipsen's Cabozantinib Hits Hurdle In Liver Cancer

Exelixis/Ipsen’s novel combination of cabozantinib and atezolizumab has produced mixed top-line results from the Phase III COSMIC-312 study, and although the companies are pressing ahead with further analyses, the doublet may struggle to compete in the first-line advanced liver cancer setting.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • X-Ceptor Therapeutics, Inc.
UsernamePublicRestriction

Register